Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma
Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma
复制标题
DOI：
10.1177/172460080201700208
复制
发表时间：
2002-04-01
影响因子：
2
通讯作者：
Vizoso, F
中科院分区：
文献类型：
--
作者：
Díaz, M;Rodríguez, JC;Vizoso, F
胃蛋白酶原C是一种天冬氨酸蛋白酶，主要参与胃中蛋白质的消化，也是乳腺癌细胞中的雄激素诱导蛋白。本研究的目的是评估该酶在前列腺癌骨转移患者原发肿瘤中接受抗雄激素治疗的表达及其临床意义。本研究对28例D2期前列腺癌患者进行了前瞻性研究，这些患者在诊断后接受了最大限度的雄激素阻断。使用免疫组织化学方法分析原发性肿瘤样本（24个来自针活检柱，4个来自经尿道切除标本）中胃蛋白酶原C的肿瘤表达。12例前列腺癌（42.8%）胃蛋白酶原C阳性。胃蛋白酶原C是我们研究中预测患者更长的总生存期的重要预后因素
Pepsinogen C is an aspartyl protease mainly involved in the digestion of proteins in the stomach, and an androgen-inducible protein in breast cancer cells. The aims of this study were to evaluate the expression and clinical significance of this enzyme in the primary tumors of prostate cancer patients with bone metastasis who were scheduled to receive antiandrogenic therapy. This study was prospectively performed in 28 stage D2 prostate cancer patients who, after diagnosis, received maximum androgen blockade. Pepsinogen C tumor expression was analyzed in samples (24 from needle biopsy cylinders and four from transurethral resection specimens) from primary tumors using an immunolhistochemical assay. Twelve prostate carcinomas (42.8%) were positive for pepsinogen C. Pepsinogen C was a significant prognostic factor to predict a longer overall survival in the patients of our study (p